IRIX - IRIDEX Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.175
+0.175 (+3.50%)
As of 10:05AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close5.000
Open5.040
Bid4.900 x 1200
Ask5.090 x 900
Day's Range4.900 - 5.250
52 Week Range4.280 - 9.600
Volume6,278
Avg. Volume28,681
Market Cap68.985M
Beta (3Y Monthly)1.42
PE Ratio (TTM)N/A
EPS (TTM)-1.304
Earnings DateMar 6, 2018 - Mar 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  • GlobeNewswire3 hours ago

    IRIDEX Announces Appointment of Robert E. Grove, Ph.D. to its Board of Directors

    IRIDEX Corporation (IRIX) today announced the appointment of Dr. Robert Grove to the Company’s Board of Directors effective October 15, 2018. Concurrently, Ann Rhoads will step down from the Board of Directors to focus attention on her new responsibility as Chief Financial Officer of Forty Seven Inc. “Bob is a perfect fit for our Board of Directors and will be an excellent addition,” said William M. Moore, Chairman and Chief Executive Officer.

  • IRIDEX Corporation (NASDAQ:IRIX): What Does It Mean For Your Portfolio?
    Simply Wall St.28 days ago

    IRIDEX Corporation (NASDAQ:IRIX): What Does It Mean For Your Portfolio?

    Anyone researching IRIDEX Corporation (NASDAQ:IRIX) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. InvestorsRead More...

  • GlobeNewswirelast month

    IRIDEX Announces Pricing of Public Offering of Common Stock

    The offering is expected to close on September 18, 2018, subject to customary closing conditions. Gross proceeds to the Company from the offering are expected to be approximately $10,000,000 before deducting the underwriting discount and other offering expenses payable by the Company and excluding any exercise of the underwriters' option.

  • GlobeNewswirelast month

    IRIDEX Announces Proposed Public Offering of Common Stock

    IRIDEX Corporation (IRIX) ("IRIDEX" or the "Company"), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. IRIDEX also expects to grant the underwriters for the offering a 30-day option to purchase an additional 15% of the shares of its common stock offered in the public offering.  All of the shares to be sold in the offering are to be sold by IRIDEX. IRIDEX intends to use the net proceeds from the offering for working capital and other general corporate purposes.

  • GlobeNewswirelast month

    IRIDEX Announces FDA Clearance to Introduce Updated TruFocus LIO Premiere™ Laser Accessory to the U.S. Market

    The TruFocus LIO Premiere is a light combination and reflection viewing system used with IRIDEX retina laser systems and is worn on the physician’s head. The product combines a laser treatment beam from an IRIDEX laser source with the illumination beam of a binocular indirect ophthalmoscope into a mixed optical beam used by a physician with a handheld ophthalmic examination lens to enter a patient’s pupil and to view and treat a patient’s retina. “We are pleased to again be offering our full portfolio of laser delivery devices to doctors in the U.S.,” said William M. Moore, President and Chief Executive Officer.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of IRIX earnings conference call or presentation 2-Aug-18 9:00pm GMT

    Q2 2018 IRIDEX Corp Earnings Call

  • GlobeNewswire2 months ago

    IRIDEX Cyclo G6™ Laser System for Glaucoma Treatment Used in Majority of Top U.S. Ophthalmology Hospitals

    IRIDEX Corporation (Nasdaq: IRIX), a leading provider of innovative laser systems in ophthalmology, is pleased to announce that the Company’s Cyclo G6 Glaucoma Laser System is used in 35 of the 39 “Best Hospitals for Ophthalmology” as ranked in a recent report by U.S. News and World Report. The Cyclo G6 system is the first in its class designed specifically to treat patients diagnosed with a range of glaucoma disease states. It features the Company’s proprietary MicroPulse® technology, in which a continuous-wave laser beam is chopped into a train of tiny, repetitive, low energy pulses separated by a brief rest period allowing the tissue to cool between laser pulses.

  • Associated Press2 months ago

    Iridex: 2Q Earnings Snapshot

    The Mountain View, California-based company said it had a loss of 28 cents per share. The medical laser company posted revenue of $10.3 million in the period. Iridex expects full-year revenue in the range ...

  • GlobeNewswire2 months ago

    IRIDEX Announces 2018 Second Quarter Results and Raises Full Year 2018 Guidance

    MOUNTAIN VIEW, Calif., Aug. 02, 2018-- IRIDEX Corporation today reported financial results for the second quarter and six months ended June 30, 2018.. Cyclo G6™ product revenue increased approximately ...

  • GlobeNewswire3 months ago

    IRIDEX to Report Second Quarter 2018 Financial Results on August 2, 2018

    MOUNTAIN VIEW, Calif., July 19, 2018-- IRIDEX Corporation today announced the Company will release financial results for the second quarter 2018 after the close of trading on Thursday, August 2, 2018. ...

  • Should You Buy IRIDEX Corporation (NASDAQ:IRIX) Now?
    Simply Wall St.4 months ago

    Should You Buy IRIDEX Corporation (NASDAQ:IRIX) Now?

    IRIDEX Corporation (NASDAQ:IRIX), a medical equipment company based in United States, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. As a smallRead More...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of IRIX earnings conference call or presentation 3-May-18 9:00pm GMT

    Q1 2018 IRIDEX Corp Earnings Call

  • Associated Press5 months ago

    Iridex: 1Q Earnings Snapshot

    On a per-share basis, the Mountain View, California-based company said it had a loss of 31 cents. The medical laser company posted revenue of $9.5 million in the period. Iridex shares have declined 27 ...

  • PR Newswire7 months ago

    Lifshitz & Miller LLP Announces Investigation of BioScrip, Inc., Civitas Solutions, Inc., Iridex Corp., OHR Pharmaceutical, Inc., Overstock.com, Inc., Syneos Health, Inc., Ubiquiti Networks, Inc. and WageWorks, Inc.

    NEW YORK , March 20, 2018 /PRNewswire/ --   BioScrip, Inc. (BIOS) Lifshitz & Miller  announces investigation into possible breaches of fiduciary duties in connection with BioScrip's disclosure that it ...

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of IRIX earnings conference call or presentation 8-Mar-18 10:00pm GMT

    Q4 2017 IRIDEX Corp Earnings Call

  • Associated Press7 months ago

    Iridex reports 4Q loss

    On a per-share basis, the Mountain View, California-based company said it had a loss of 44 cents. The medical laser company posted revenue of $10.2 million in the period. For the year, the company reported ...

  • ACCESSWIRE7 months ago

    IRIDEX Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 8, 2018 / IRIDEX Corporation (NASDAQ: IRIX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018, at 5:00 PM Eastern Time. ...